The COVID-19 pandemic laid bare a stark reality: a decades-long decline in Canada’s biopharmaceutical industry had left the country without the manufacturing capacity required to quickly produce life-saving vaccines and therapies.

In response, the Government of Canada launched an ambitious $2.2 billion strategy to revitalize the sector.

McGill’s new Master’s of Engineering in biomanufacturing is training skilled workers to support the growth of this important sector. The program will give students advanced instruction and hands-on experience through internships with industry and government partners.

Learn more about the program: [ Ссылка ]

Discover RNA research at McGill: [ Ссылка ]

свернуть